

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/035,914		
		Filing Date	November 7, 2001		
		First Named Inventor	David E. Weinstein		
		Group Art Unit	1645		
		Examiner Name	TBA		
Sheet	2	of	4	Attorney Docket Number	96700/677

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
ms	1	BOISMENU et al., A role for CD81 in early T cell development. Science, 271:198-200, 1996.	
	2	CHOMCZYNSKI and SACCHI, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry, 162:156-59, 1987.	
	3	EASTER, JR. et al., Initial tract formation in the mouse brain. Journal of Neuroscience, 13:285-99, 1993.	
	4	EDMONDSON et al., Astrotactin: a novel neuronal cell surface antigen that mediates neuron-astroglial interactions in cerebellar microcultures. Journal of Cell Biology, 106:505-17, 1988.	
	5	FLINT et al., Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. Journal of Virology, 73:6235-44, 1999.	
	6	FRISEN et al., Rapid, widespread, and longlasting induction of nestin contributes to the generation of glial scar tissue after CNS injury. Journal of Cell Biology, 131:453-64, 1995.	
	7	FUJITA, Quantitative analysis of cell proliferation and differentiation in the cortex of the postnatal mouse cerebellum. Journal of Cell Biology, 32:277-87, 1967.	
	8	GEISERT et al., Astrocyte growth, reactivity, and the target of the antiproliferative antibody, TAPA. J. Neurosci., 16:5478-87, 1996.	
	9	GIMENEZ Y RIBOTTA et al., Oxysterol (7 beta-hydroxycholesteryl-3-oleate) promotes serotonergic reinnervation in the lesioned rat spinal cord by reducing glial reaction. Journal of Neuroscience Research, 41:79-95, 1995.	
	10	HATTEN, Riding the glial monorail: a common mechanism for glial-guided neuronal migration in different regions of the developing mammalian brain. Trends in Neuroscience, 13:179-84, 1990.	
ms	11	HATTEN and LIEM, Astroglial cells provide a template for the positioning of developing cerebellar neurons in vitro. Journal of Cell Biology, 90:622-30, 1981.	

Examiner Signature	<i>Diana</i>	Date Considered	12/31/03
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

AUG 13 2002

TECH CENTER 1600/2900



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/035,914
		Filing Date	November 7, 2001
		First Named Inventor	David E. Weinstein
		Group Art Unit	1645
		Examiner Name	TBA
		Attorney Docket Number	96700/677
Sheet	3	of	4

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
Mj	12	HATTEN et al., Neuron-astroglial interactions in vitro and their implications for repair of CNS injury. Central Nervous System Trauma, 1:15-27, 1984.	
	13	HATTEN and SHELANSKI, Mouse cerebellar granule neurons arrest the proliferation of human and rodent astrocytoma cells in vitro. Journal of Neuroscience, 8:1447-53, 1988.	
	14	KELIC et al., CD81 regulates neuron-induced astrocyte cell-cycle exit. Molecular and Cellular Neuroscience, 17:551-60, 2001.	
	15	KOPCZYNSKI et al., A neural tetraspanin, encoded by late bloomer, that facilitates synapse formation, Science, 271:1867-70, 1996.	
	16	LATOV et al., Fibrillary astrocytes proliferate in response to brain injury. Developmental Biology, 72:381-84, 1979.	
	17	MAECKER et al., CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc. Natl Acad. Sci. USA, 95:2458-62, 1998.	
	18	MAECKER and LEVY, Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J. Exp. Med., 185:1505-10, 1997.	
	19	MAECKER et al., Differential expression of murine CD81 highlighted by new anti-mouse CD81 monoclonal antibodies. Hybridoma, 19:15-22, 2000.	
	20	MAECKER et al., The tetraspanin superfamily: molecular facilitators. FASEB J., 11:428-42, 1997.	
	21	MIYAZAKI et al., Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J., 16:4217-25, 1997.	
	Dray	22	PEDRAM et al., Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction. J. Biol. Chem., 273:13966-72, 1998.

Examiner Signature	<i>Drana</i>	Date Considered	12/31/03
--------------------	--------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
AUG 13 2002  
TECH CENTER 1600/2000



PTO/SB/088 (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
		Application Number	10/035,914
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	November 7, 2001
		First Named Inventor	David E. Weinstein
		Group Art Unit	1645
		Examiner Name	TBA
		Attorney Docket Number	96700/677
Sheet	4	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
D E	23	PEDUZZI et al., The expression of TAPA (CD81) correlates with the reactive response of astrocytes in the developing rat CNS. Experimental Neurology, 160:460-48, 1999.	
	24	STITT and HATTEN, Antibodies that recognize astrotactin block granule neuron binding to astroglia. Neuron, 5:639-49, 1990.	
	25	STURROCK, Histogenesis of the anterior limb of the anterior commissure of the mouse brain III. An electron microscope study of gliogenesis. Journal of Anatomy, 117:37-53, 1974.	
	26	STURROCK, Histogenesis of the anterior limb of the anterior commissure of the mouse brain. I. A quantitative study of changes in the glial population with age. Journal of Anatomy, 117:17-25, 1974.	
	27	STURROCK, Histogenesis of the anterior limb of the anterior commissure of the mouse brain. II. A quantitative study of pre- and postnatal mitosis. Journal of Anatomy, 117:27-35, 1974.	
	28	TEIXEIRA et al., Differential regulation of cyclin D1 and D3 expression in the control of astrocyte proliferation induced by endothelin-1. Journal of Neurochemistry, 74:1034-40, 2000.	
	29	TSITSIKOV et al., Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81- deficient mice. Proc. Natl Acad. Sci. USA, 94:10844-49, 1997.	
	30	WEINSTEIN et al., C17, a retrovirally immortalized neuronal cell line, inhibits the proliferation of astrocytes and astrocytoma cells by a contact-mediated mechanism. Glia, 3:130-39, 1990.	
	31	WEINSTEIN et al., Suppression by antisense mRNA demonstrates a requirement for the glial fibrillary acidic protein in the formation of stable astrocytic processes in response to neurons. Journal of Cell Biology, 112:1205-13, 1991.	
	D E	32	BEERS and BERKOW, eds., The Merck Manual of Diagnosis and Therapy, 17th ed. (Whitehouse Station, NJ: Merck Research Laboratories, 1999) 1395-1398, 1442-48.


Examiner Signature	<i>Diana B...</i>	Date Considered	12/31/03
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
AUG 13 2002  
TECH CENTER 16002900



Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet

1

of

4

**Complete if Known**

<b>Application Number</b>	10/035,914
<b>Filing Date</b>	November 7, 2001
<b>First Named Inventor</b>	David E. Weinstein
<b>Art Unit</b>	1645
<b>Examiner Name</b>	TBA
<b>Attorney Docket Number</b>	96700/677

[illegible]

TECH CENTER 1600/2900

[illegible]

12/31/02

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**